sever
author
state
pharmaceut
industri
face
product
crisi
stagnanc
number
new
drug
approv
increas
expenditur
research
develop
process
among
sever
strategi
depict
solv
problem
natur
product
propos
molecul
could
effect
introduc
pharmaceut
market
undoubtedli
natur
product
produc
result
million
year
evolut
terrestri
marin
organ
struggl
adapt
number
abiot
biotic
stress
therefor
encod
bioactiv
natur
product
histor
use
pharmaceut
industri
discoveri
bioactiv
compound
precursor
develop
new
activ
molecul
exampl
paclitaxel
docetaxel
vincristin
vinblastin
penicillin
recent
trabectedin
romidepsin
recent
use
standar
herbal
extract
clear
exampl
develop
new
botan
drug
veregen
fulyzaq
current
approv
us
feder
drug
administr
fda
treatment
genit
wart
hivassoci
diarrhea
respect
addit
sativex
titrat
extract
contain
approv
sinc
sever
countri
canada
uk
germani
new
zealand
treatment
spastic
due
multipl
sclerosi
central
peripher
neuropath
pain
variou
origin
context
clear
advanc
rapid
genom
sequenc
coupl
manipul
biosynthet
pathway
well
recent
advanc
metagenom
may
provid
vast
resourc
futur
discoveri
pharmaceut
agent
deriv
natur
product
calophyllum
genu
larg
group
tropic
tree
speci
belong
calophyllacea
famili
speci
repres
import
sourc
natur
product
mainli
distribut
tropic
region
asia
africa
america
australasia
pacif
island
speci
contain
coumarin
xanthon
signific
biolog
activ
cytotox
antivir
chemoprevent
antisecretori
cytoprotect
analges
antimicrobi
speci
genu
use
folk
medicin
treat
peptic
ulcer
malaria
tumor
infect
vener
diseas
hypertens
pain
inflamm
among
health
problem
calophyllum
speci
quit
complex
difficult
classifi
even
taxonomist
studi
genu
speak
confus
frustrat
experienc
tri
differenti
speci
seem
challeng
establish
definit
boundari
calophyllum
genu
belong
famili
plant
known
calophyllacea
accord
classif
system
apgiii
angiosperm
phylogeni
group
formal
includ
clusiacea
guttifera
segreg
consist
nearli
speci
thrive
old
world
distribut
mainli
indomalaysian
region
import
one
c
inophyllum
hand
eight
speci
found
new
world
distribut
mexico
argentina
caribbean
region
import
one
c
brasiliens
widespread
belief
taxon
origin
american
speci
genu
speci
genu
mediums
tree
although
high
other
shrub
wet
tropic
rainforest
lowland
habitat
speci
found
drier
area
higher
altitud
mani
flood
area
sever
taxonom
characterist
genu
outer
bark
red
diamondshap
fissur
opposit
arrang
leav
distinct
narrow
parallel
vein
altern
resin
canal
often
born
petiol
infloresc
racim
thyrs
flower
grow
leaf
axil
end
branch
termin
axillari
infloresc
sepal
petal
arrang
hermaphrodit
flower
fruit
berri
drupe
fruit
thin
layer
flesh
larg
seed
produc
white
yellow
latex
fig
first
chemic
analysi
calophyllum
publish
polonski
ormanceypoti
author
elucid
chemic
structur
inophylollid
calophylollid
calophyl
acid
isol
leav
fruit
c
inophyllum
afterward
sever
speci
wide
studi
phytochem
content
gener
speak
calophyllum
genu
wide
varieti
triterpen
belong
differ
group
fridelan
fridelin
fridelan
canophyllol
oleanan
canophyl
acid
apetalacton
lupan
betulin
acid
taraxeran
taraxerol
taraxeron
final
group
adianan
polyphenol
flavonoid
mainli
quercetin
epicatechin
isol
leav
sever
speci
genu
also
small
phenol
compound
gallic
acid
shikim
acid
protocatechu
acid
isol
leav
coumarin
fig
chromanon
common
genu
speci
biosynthes
compound
leav
use
biomark
metabolit
exhibit
interest
pharmacolog
activ
xanthon
fig
isol
wood
bark
sever
speci
genu
sever
kind
coumarin
isol
leav
bark
fruit
latex
calophyllum
speci
among
tricycl
tetracycl
mammea
type
fig
show
ic
ae
mm
even
reach
clinic
phase
ii
show
appar
safe
therapeut
level
plasma
inophyllum
isol
mainli
c
inophyllum
also
shown
activ
hiv
exampl
inophyllum
b
p
shown
ic
nm
respect
cordatolid
b
isol
c
cordatooblongum
shown
ic
includ
six
human
leukem
cell
line
sem
pglycoprotein
overexpress
cell
line
compound
induc
caspasemedi
cell
death
cell
interestingli
coumarin
mammea
aba
abb
bbb
also
shown
activ
trypanosoma
cruzi
leishmania
amazonensi
induc
disrupt
mitochondri
swell
loss
normal
ultrastructur
parasit
xanthon
also
shown
activ
compon
genu
numer
pharmacolog
activ
fig
detail
inform
pharmacolog
activ
xanthon
isol
differ
calophyllum
speci
accord
scopu
databas
present
tabl
seven
antimalari
xanthon
isol
c
caledonicum
ic
mgml
four
xanthon
isol
c
brasiliens
show
inhibitor
sulfotransferas
valu
ic
mm
xanthon
isol
c
brasiliens
also
reveal
activ
chaga
diseas
ic
mm
valu
tripomastigot
xanthon
also
possess
antivir
activ
instanc
five
pyranoxanthon
isol
c
blancoi
show
highli
activ
coronaviru
ec
mgml
addit
brasixanthon
ad
isol
c
brasiliens
display
percent
antiprolif
activ
epsteinbarr
viru
raji
cell
line
chemoinformat
also
call
cheminformat
chemic
inform
scienc
variou
definit
exampl
applic
informat
method
solv
chemic
problem
predict
possibl
toxicolog
properti
deriv
directli
structur
data
compar
previous
known
experiment
toxic
toxicoinformat
consid
interfac
chemistri
informat
collect
method
use
drug
design
discoveri
chemoinformat
compris
plethora
comput
techniqu
organ
mine
visual
analyz
divers
coverag
chemic
space
compound
collect
promin
wide
use
exampl
lipinski
rule
five
rule
five
denot
set
properti
rule
describ
oral
bioavail
drug
space
briefli
pharmaceut
industri
notic
mani
compound
termin
clinic
develop
unsatisfactori
pharmacokinet
pk
lipinski
analyz
attrit
problem
pharmaceut
industri
came
surpris
conclus
simpl
set
physicochem
paramet
associ
percent
oral
activ
drug
achiev
phase
ii
statu
paramet
later
call
rule
five
compris
follow
hydrogenbond
donor
molecular
mass
calcul
log
p
partit
coeffici
water
sum
nitrogen
oxygen
atom
hydrogenbond
acceptor
extens
rule
polar
surfac
area
sum
hbond
donor
acceptor
rotat
bond
compound
success
pass
rule
could
call
druggabl
druglik
candid
drug
conform
rule
tend
lower
attrit
rate
clinic
trial
henc
increas
chanc
reach
market
rule
one
first
exampl
chemoinformat
drug
develop
chemoinformat
treat
molecul
graph
descriptor
associ
featur
mainli
physicochem
properti
biolog
activ
ensembl
graph
set
molecul
descriptor
form
chemic
space
relationship
compound
must
defin
basic
concept
chemoinformat
rule
chemoinformat
explicitli
taken
rigor
physic
model
rather
learn
induct
data
context
tool
word
chemoinformat
help
order
analyz
natur
product
poss
highli
complex
structur
use
chemoinfomat
approach
natur
product
databas
could
help
reduc
hit
multipl
improv
process
hittolead
identif
natur
product
np
select
evolut
bind
variou
protein
life
cycl
eg
biosynthesi
degrad
exert
mode
action
result
np
structur
good
start
point
discoveri
develop
protein
ligand
ultim
drug
discoveri
np
gener
constitut
biolog
valid
start
point
librari
design
mani
core
structur
recogn
privileg
structur
eg
benzodiazepin
henkel
et
al
publish
first
work
natur
product
pharmacophor
group
analyz
found
structur
unit
prone
interact
biolog
macromolecul
late
lee
shenid
compar
set
paramet
relat
lipinski
rule
five
trade
drug
natur
product
discov
natur
product
molecul
contain
averag
nitrogen
atom
per
molecul
one
less
drug
set
calcul
log
p
valu
indic
natur
product
lipophil
drug
molecul
vs
surprisingli
percent
molecul
violat
rule
five
feher
schmidt
found
natur
product
averag
contain
two
oxygen
atom
unsatur
possess
fewer
sulphur
halogen
atom
addit
number
rotat
bond
two
time
less
commerci
drug
indic
natur
product
rigid
molecul
common
drug
result
confirm
later
ertl
schuffenhau
test
higher
databas
natur
product
molecul
includ
marin
product
confirm
major
natur
product
violat
rule
five
natur
product
differ
drug
heteroatom
distribut
number
ring
degre
ring
fusion
addit
lipophil
natur
product
must
consid
heterogen
group
vari
accord
origin
organ
current
environ
role
natur
feher
schmidt
also
analyz
natur
product
seminatur
deriv
interest
note
found
seminatur
deriv
possess
high
rate
druglik
properti
indic
spite
complex
heterogen
molecul
natur
product
may
serv
appropri
inspir
new
drug
design
among
main
problem
drug
develop
new
drug
discoveri
toxic
advers
effect
furthermor
estim
percent
failur
clinic
phase
address
toxicolog
issu
advers
effect
therefor
becom
quit
import
assay
new
activ
compound
toxicolog
avail
test
clinic
test
context
use
new
technolog
comput
approach
becom
quit
import
silico
approach
less
expens
vitro
vivo
experi
could
help
make
accur
decis
drug
develop
last
year
toxicolog
improv
greatli
develop
new
tool
test
becom
relat
recent
disciplin
chemistri
ecolog
genom
epidemiolog
statist
new
subspeci
arisen
ecotoxicolog
forens
toxicolog
molecular
clinic
toxicolog
toxicogenom
toxicogenet
name
exampl
disciplin
grown
amount
new
data
toxic
inform
raw
data
laboratori
field
data
statist
epidemiolog
report
hazard
monitor
exposur
data
regulatori
inform
visual
imag
patholog
genet
express
proteom
data
physicochem
properti
qsar
analysi
context
toxicoinformat
emerg
subdisciplin
divid
two
term
first
collect
manag
dissemin
data
second
understand
complex
molecular
mechan
toxic
obtain
new
inform
databas
could
help
prevent
predict
treat
toxicolog
effect
chemic
inform
inher
part
toxicolog
domain
develop
chemoinformat
support
progress
toxicolog
number
new
compound
discov
per
year
estim
million
inform
avail
compound
eg
pharmacolog
toxicolog
activ
bibliograph
text
physicochem
properti
structur
reaction
among
other
avail
line
sever
public
databas
therefor
use
sever
chemoinformat
methodolog
chemic
space
may
help
predict
possibl
toxicolog
properti
deriv
directli
chemic
structur
data
chemic
space
form
comparison
differ
properti
compound
known
toxic
toxicoinformat
sever
toxicoinformat
databas
alreadi
publish
avail
onlin
sone
et
al
publish
pcec
profil
chemic
effect
cell
toxicolog
databas
system
classifi
chemic
effect
human
health
databas
store
handl
gene
express
profil
inform
categori
toxic
data
toxicolog
data
networktoxnet
http
wwwtoxnetnlmnihgov
webbas
inform
system
provid
access
inform
regard
medic
occup
pharmacokinet
toxicolog
environment
effect
biolog
chemic
substanc
maintain
nation
librari
medicin
divis
special
inform
servic
section
nih
one
popular
resourc
chemoinformat
toxicoinformat
approach
osiri
properti
explor
allow
user
draw
chemic
structur
calcul
variou
onthefli
drugrelev
properti
draw
structur
toxic
risk
predictor
start
look
potenti
toxic
risk
mutagen
tumorigen
irrit
effect
reproduct
effect
toxic
risk
alert
indic
drawn
structur
may
harm
concern
risk
categori
specifi
predict
process
reli
precomput
set
structur
fragment
give
rise
toxic
alert
case
found
structur
current
drawn
afterward
substructur
search
process
determin
frequenc
fragment
ie
core
construct
fragment
occur
within
compound
toxic
class
sinc
fragment
frequenc
belong
structur
trade
drug
base
assumpt
trade
drug
larg
free
toxic
effect
fragment
consid
risk
factor
occur
often
substructur
harm
compound
never
rare
trade
drug
interest
databas
toxicolog
inform
applic
use
toxicolog
silico
approach
compar
toxicogenom
databas
http
ctdbaseorg
toxpredict
http
appsideaconsultnet
toxpredict
leadscop
toxic
databas
http
wwwleadscopecom
howev
detail
analysi
beyond
purpos
review
accord
review
bibliograph
analysi
toxicoinformat
approach
novel
studi
toxicoinformat
analysi
natur
product
databas
saxena
test
natur
compound
use
test
toxic
estim
softwar
tool
predict
mutagen
valu
indic
natur
compound
may
posit
paramet
context
introduct
toxicoinformat
studi
natur
product
repres
novel
subject
could
help
improv
pharmaceut
develop
type
compound
could
help
develop
new
librari
novel
structur
deriv
natur
bioactiv
molecul
previous
mention
import
emphas
mani
properti
natur
product
could
depend
strongli
data
chemic
space
analyz
context
obtain
main
properti
princip
activ
coumarin
xanthon
isol
calophyllum
genu
order
analyz
potenti
drug
lead
inspir
molecul
design
new
drug
done
set
chemic
space
group
accord
main
physicochem
toxicolog
properti
use
osiri
molinspir
properti
explor
chemoinfomat
analysi
consist
obtain
main
theoret
physicochem
chemmin
toolsjoellib
descriptor
toxicolog
properti
osirisdatawarrior
determin
whether
compound
could
consid
develop
new
drug
lead
hit
drugabl
list
contain
coumarin
xanthon
along
result
physicochem
properti
tabl
appendix
physicochem
properti
coumarin
xanthon
calcul
use
chemminetool
base
joellib
descriptor
summari
main
properti
present
tabl
follow
properti
evalu
mw
log
p
number
hba
number
hbd
acid
group
aliphat
oh
basic
group
frb
heavi
bond
heterocycl
hydrophob
group
mr
number
atom
number
halogen
atom
b
br
cl
f
n
p
number
bond
tabl
show
summari
comparison
main
properti
coumarin
xanthon
molecular
differ
type
compound
molecular
weight
number
bond
log
p
druglik
molecular
refract
psa
surpris
coumarin
possess
higher
molecular
weight
complex
structur
explain
main
differ
properti
interest
note
xanthon
possess
higher
valu
druglik
coumarin
similar
pattern
physicochem
properti
howev
heterogen
molecular
weight
mw
molecular
refract
mr
number
atom
number
bond
polar
surfac
area
psa
inocalophyllin
b
inocalophyllin
methyl
ester
particular
cluster
possess
higher
score
mw
mr
structur
complex
higher
number
doubl
bond
ie
higher
valu
polariz
mole
subtanc
grant
mention
properti
fig
hand
xanthon
isol
calophyllum
spp
tabl
possess
pattern
physicochem
properti
unlik
coumarin
compound
greater
structur
homogen
chemoinformat
analysi
indic
coumarin
fig
xanthon
fig
complianc
lipinski
rule
five
among
group
two
compound
caledonixanthoneb
possess
potenti
leadlik
fig
also
member
compound
librari
follow
lipinski
rule
five
well
rule
three
log
p
greater
molecular
mass
less
dalton
hydrogen
bond
donor
hydrogen
bond
acceptor
rotat
bond
easier
fast
time
deliv
optim
drug
develop
candid
compound
caledonixanthoneb
isol
c
caledonium
none
test
pharmacolog
properti
therefor
molecul
test
swisstarget
predict
tool
avail
onlin
predict
bioactiv
molecul
target
base
similar
known
ligand
alreadi
known
drug
interestingli
percent
probabl
interact
maoa
maob
speak
potenti
antidepress
drug
correl
literatur
sever
studi
xanthon
mao
inhibit
hand
caledonixanthon
b
percent
probabl
interact
dualspecif
tyrosinephosphorylationregul
kinas
overexpress
varieti
diseas
includ
number
human
malign
haematolog
brain
cancer
interest
note
compound
prove
activ
differ
tumor
cell
line
howev
data
experiment
test
order
valid
result
coumarin
xanthon
log
valu
less
complianc
drug
percent
trademark
drug
estim
log
greater
interest
aqueou
solubl
compound
significantli
affect
absorpt
distribut
characterist
side
coumarin
fig
xanthon
fig
isol
calophyllum
spp
neg
valu
druglik
howev
import
highlight
posit
valu
state
molecul
contain
mainli
fragment
frequent
present
commerci
drug
although
nt
necessarili
mean
fragment
well
balanc
concern
properti
instanc
molecul
may
druglik
moieti
due
lipophil
fragment
molecul
high
druglik
score
although
would
nt
realli
qualifi
drug
high
lipophil
result
indic
coumarin
eg
inocalophyllin
b
methylesth
mammea
aaa
dehydrocyclo
f
aba
cyclo
f
cob
coa
cab
aba
cyclo
f
xanthon
eg
hydroxydihydrofuranodemethylcalabaxanthon
butyl
xanthon
apetalinon
structur
modifi
order
easili
formul
introduc
clinic
low
valu
druglik
toxic
one
handicap
issu
molecul
use
clinic
test
develop
approv
drug
regard
toxic
four
coumarin
mammea
aab
dioxycalanocyclof
inophyllum
calocoumarin
c
theoret
possess
high
reproduct
tumorigen
irrit
effect
hand
coumarin
possess
reproduct
irrit
effect
coumarin
tumorigen
reproduct
mutagen
irrit
effect
inocalophyllin
b
methyl
ether
disparfuran
b
gut
mucigerin
mammea
aaa
aaa
dehydrocyclo
f
coa
aba
bba
bba
cyclo
f
abd
aba
cyclo
f
bba
cob
abd
result
indic
coumarin
studi
order
investig
possibl
reproduct
effect
well
irrit
properti
identifi
structur
could
improv
get
better
therapeut
result
last
properti
probabl
detect
studi
osiri
datawarrior
involv
algorithm
relat
toxicolog
properti
structur
sever
exampl
commerci
coumarin
possess
irrit
properti
osthol
byakangelicin
use
cosmet
properti
could
improv
chang
type
formul
compound
irrit
skin
nonetheless
interact
reproduct
effect
must
deepli
studi
use
type
reproduct
tumorigen
effect
nevertheless
could
poss
highli
mutagen
effect
result
indic
xanthon
experiment
investig
order
delv
mutagen
properti
could
consid
clinic
pharmacolog
biolog
research
calophyllum
spp
increas
last
year
due
potenti
import
sourc
pharmacolog
activ
compound
intracellular
parasit
cancer
cell
line
among
other
studi
focus
experiment
toxicolog
research
reproduct
mutagen
effect
well
structur
improv
order
valid
whether
xanthon
coumarin
real
opportun
develop
new
activ
drug
vast
major
xanthon
coumarin
isol
genu
complianc
lipinski
rule
five
even
two
xanthon
caledonixanthoneb
leadlik
potenti
appar
could
interact
mao
respect
chemotoxicoinformat
analysi
properti
calcul
data
visual
determin
use
freeli
avail
softwar
datawarriorcheminformat
program
data
visual
analysi
chemic
cluster
heatmap
calcul
visual
use
chemmin
tool
onlin
servic
analyz
cluster
small
molecul
numer
data
cluster
perform
accordingli
euclidian
distanc
column
zscore
calcul
properti
base
singl
linkag
method
numer
data
properti
base
joelib
descriptor
target
search
compound
chemoinformat
analysi
possibl
target
perform
swisstarget
predict
onlin
server
swiss
institut
bioinformat
http
wwwswisstargetpredictionch
access
juan
carlo
gomez
verjan
grate
doctorado
en
ciencia
biom
edicasunam
conacyt
provid
scholarship
number
work
submit
fulfil
requir
earn
phd
doctorado
en
ciencia
biom
edica
universidad
nacion
de
exico
karla
daniela
grate
doctorado
en
ciencia
biom
edicasunam
conacyt
provid
scholarship
number
research
support
grant
dgapaunam
inhibitori
concentr
percent
mic
minimum
inhibitori
concentr
ec
concentr
increas
alkalin
phosphatas
ld
lethal
dose
percent
